6NIU

Crystal structure of a human anti-ZIKV-DENV neutralizing antibody MZ4 in complex with ZIKV E glycoprotein


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 4.30 Å
  • R-Value Free: 0.359 
  • R-Value Work: 0.264 
  • R-Value Observed: 0.269 

wwPDB Validation   3D Report Full Report


This is version 1.2 of the entry. See complete history


Literature

Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor.

Dussupt, V.Sankhala, R.S.Gromowski, G.D.Donofrio, G.De La Barrera, R.A.Larocca, R.A.Zaky, W.Mendez-Rivera, L.Choe, M.Davidson, E.McCracken, M.K.Brien, J.D.Abbink, P.Bai, H.Bryan, A.L.Bias, C.H.Berry, I.M.Botero, N.Cook, T.Doria-Rose, N.A.Escuer, A.G.I.Frimpong, J.A.Geretz, A.Hernandez, M.Hollidge, B.S.Jian, N.Kabra, K.Leggat, D.J.Liu, J.Pinto, A.K.Rutvisuttinunt, W.Setliff, I.Tran, U.Townsley, S.Doranz, B.J.Rolland, M.McDermott, A.B.Georgiev, I.S.Thomas, R.Robb, M.L.Eckels, K.H.Barranco, E.Koren, M.Smith, D.R.Jarman, R.G.George, S.L.Stephenson, K.E.Barouch, D.H.Modjarrad, K.Michael, N.L.Joyce, M.G.Krebs, S.J.

(2020) Nat Med 26: 228-235

  • DOI: 10.1038/s41591-019-0746-2
  • Primary Citation of Related Structures:  
    6MTX, 6MTY, 6NIP, 6NIS, 6NIU

  • PubMed Abstract: 
  • Zika virus (ZIKV) has caused significant disease, with widespread cases of neurological pathology and congenital neurologic defects. Rapid vaccine development has led to a number of candidates capable of eliciting potent ZIKV-neutralizing antibodies (reviewed in refs ...

    Zika virus (ZIKV) has caused significant disease, with widespread cases of neurological pathology and congenital neurologic defects. Rapid vaccine development has led to a number of candidates capable of eliciting potent ZIKV-neutralizing antibodies (reviewed in refs. 1-3 ). Despite advances in vaccine development, it remains unclear how ZIKV vaccination affects immune responses in humans with prior flavivirus immunity. Here we show that a single-dose immunization of ZIKV purified inactivated vaccine (ZPIV) 4-7 in a dengue virus (DENV)-experienced human elicited potent cross-neutralizing antibodies to both ZIKV and DENV. Using a unique ZIKV virion-based sorting strategy, we isolated and characterized multiple antibodies, including one termed MZ4, which targets a novel site of vulnerability centered on the Envelope (E) domain I/III linker region and protects mice from viremia and viral dissemination following ZIKV or DENV-2 challenge. These data demonstrate that Zika vaccination in a DENV-experienced individual can boost pre-existing flavivirus immunity and elicit protective responses against both ZIKV and DENV. ZPIV vaccination in Puerto Rican individuals with prior flavivirus experience yielded similar cross-neutralizing potency after a single vaccination, highlighting the potential benefit of ZIKV vaccination in flavivirus-endemic areas.


    Organizational Affiliation

    Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA. skrebs@hivresearch.org.



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
Human MZ4 Fab heavy chainG [auth F], A [auth H], I, K [auth M]120Homo sapiensMutation(s): 0 
Protein Feature View
Expand
  • Reference Sequence
Find similar proteins by:  (by identity cutoff)  |  Structure
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetailsImage
Human MZ4 Fab light chainH [auth G], J, B [auth L], L [auth N]111Homo sapiensMutation(s): 0 
Protein Feature View
Expand
  • Reference Sequence
Find similar proteins by:  (by identity cutoff)  |  Structure
Entity ID: 3
MoleculeChainsSequence LengthOrganismDetailsImage
Envelope protein ED [auth A], C [auth B], F [auth E], E [auth Z]447Zika virus ZIKV/H. sapiens/FrenchPolynesia/10087PF/2013Mutation(s): 0 
EC: 3.4.21.91 (UniProt), 3.6.1.15 (UniProt), 3.6.4.13 (UniProt), 2.1.1.56 (UniProt), 2.1.1.57 (UniProt), 2.7.7.48 (UniProt)
UniProt
Find proteins for A0A024B7W1 (Zika virus (isolate ZIKV/Human/French Polynesia/10087PF/2013))
Explore A0A024B7W1 
Go to UniProtKB:  A0A024B7W1
Protein Feature View
Expand
  • Reference Sequence
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 4.30 Å
  • R-Value Free: 0.359 
  • R-Value Work: 0.264 
  • R-Value Observed: 0.269 
  • Space Group: P 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 113.53α = 80.12
b = 137.26β = 65.74
c = 136.79γ = 65.75
Software Package:
Software NamePurpose
PHENIXrefinement
PDB_EXTRACTdata extraction
HKL-2000data reduction
HKL-2000data scaling
PHASERphasing

Structure Validation

View Full Validation Report




Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Other governmentUnited StatesW81XWH-07-2-0067

Revision History  (Full details and data files)

  • Version 1.0: 2019-12-25
    Type: Initial release
  • Version 1.1: 2020-02-19
    Changes: Database references
  • Version 1.2: 2020-02-26
    Changes: Database references